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Letters to the Editor
CUTANEOUS MELANOMA IN SCOTLAND
SrR,-Professors Mackie and Hunter (Br.
J. Cancer, 46, 75-80) quote a rate of 3-0/105
as the Scottish Rate for cutaneous melanoma
derived from Cancer Registry Data and
suggest that the discrepancy between this
and the Scottish Melanoma Group Rate of
5-1/105 is due to previous under-registration
in the West of Scotland (population- 3m.).
West of Scotland Cancer Registry Data
have recently improved and 3-year average
rates for cutaneous melanoma are 4-04/105
for 1975-77 (Gillis et al., 1982) and 4.4/105 for
the period 1978-80; the 1980 rate being
5-1/105. While it may be unwise to base con-
clusions on a single annual rate, especially
for a tumour of low incidence, these figures
suggest an upward trend. The extent to
which this may be due to improvements in
registration or a genuine increase in the inci-
dence of the disease remains to be deter-
mined. The fact that Cancer Registry figures
for the West of Scotland appear to be higher
than the Scottish Melanoma Group figure of
3.5/105 for the Grampian Region, while of
interest, further stresses the importance of
joint efforts by the Scottish Melanoma Group
and local Cancer/Registries to determine the
true incidence and the direction of secular
trends as clues to aetiology.
C. R. GILLIS
D. J. HOLE
West ofScotland Cancer Surveillance Unit,
Greater Glasgow Health Board,
Ruchill Hospital,
Glasgow 020 9NB
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REPLY TO LETTER BY DRS GILLIS AND HOLE
SIR,-We are interested inthe comments of
Drs Gillis and Hole and are pleased to note
that West of Scotland Cancer Registry
figures for malignant melanoma have im-
proved since submission of our paper. The
1979 figures collected by the West ofScotland
Cancer Registry are still, however, lower than
those gathered by the Scottish Melanoma
Group. A likely reason for this important
discrepancy is the fact that Scottish
Melanoma Group registration is based on
reports directly from pathology departments,
whereas in certain hospitals in the West of
Scotland Cancer Registry data are, or have
been, indirectly dependent in part on input
from secretarial staff in clinical departments
or records office staff. We have no doubt that
the Scottish Melanoma Group method of
registration is the more accurate and would
encourage its adoption by the Cancer
Registries. This is further underlined by the
fact that the West of Scotland Scottish
Melanoma Group figure for malignant
melanoma incidence in 1980 is 5-6/105 com-
pared with the lower figure of 5-1/105 quoted
by Dr Gillis from Cancer Registry data. This
represents non-registration of 15 patients
by the Cancer Registry.
As the figure of 3-5 x 105 for Grampian is
based on a very small number of cases (23)
we would not advocate drawing conclusions
relating to the whole of Scotland.
The Scottish Melanoma Group would
welcome fuller and more complete collabo-
ration with the Cancer Registries. Our data
have always been freely available to the
Cancer Registries and in the West ofScotland
personnel from the Cancer Registries have
made use of them. Reciprocity of this
arrangement and exchange of data would be
most welcome. At this time when there is
mounting evidence of a rising incidence of
malignant melanoma in such countries as
Australia and Scandinavia it is vital that
accurate incidence figures be obtained where-
ever this is possible.
R. M. MAcKIE
J. A. A. HUNTER